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Abstract
Background: Due to a growing discrepancy between the transplant waiting list and decreasing numbers of
available donor hearts, cardiac transplantation rates in Germany have been declining in the past years. Currently,
patients on the waiting list are prioritized by medical urgency and waiting time and therefore a majority of all
cardiac transplants is performed in very ill patients. Recently, a different allocation algorithm was proposed that
included predicted post-transplant survival as a parameter for organ allocation. So far, little data exists on how such
a “Cardiac Allocation Score” (CAS) relates to our current transplant patient population and on how such a change in
organ allocation could change clinical practice.
Methods: We calculated a theoretical retrospective Cardiac Allocation Score for 73 patients recruited and
transplanted at our medium-volume center in Germany based on a hypothetical scoring algorithm recently
published by Eurotransplant.
Results: Overall, 37 patients (50.7%) were transplanted on high urgency status (HU), 27 (37%) were being
supported by a VAD at time of transplant. 57 (78.1%) were male. We found a relatively normal distribution of the
hypothetical CAS with a median of 32.91 and a mean of 31.95 +/−10.02. Overall, CAS-Scores were lower than
previously described for a Eurotransplant patient cohort of high urgency patients, but there was a significant
overlap in score values between patients on HU and T status. CAS-values of VAD-supported patients were lower
than in patients without mechanical support. The IMPACT-score as part of the CAS was used for prediction of post-
transplant survival and seems suitable to predict outcome in our patient population.
Conclusion: In a retrospective analysis, the recently proposed Cardiac Allocation Score seems to show a normal
distribution of priority values in our patient cohort. The IMPACT-score predicted outcome after transplantation and
could serve as part of the CAS-algorithm to predict post-transplant survival in this single center real-world scenario.
Implementation of the CAS could significantly change organ allocation practice, including a potential prioritization
of current T-status patients over HU-status patients.
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Background
The prevalence of heart failure is steadily increasing and
has reached epidemic proportions in Germany and Eur-
ope. Approximately 1–2% of all adults suffer from heart
failure, with a prevalence of more than 10% in the aging
population above 70 years of age [1].
In the past decades, pharmacological treatment of
heart failure with a reduced ejection fraction has been a
story of great success, with significant improvements of
morbidity and mortality. In addition, cardiac devices and
surgical and interventional techniques now offer a wide
selection of therapeutic options for patients with heart
failure and are well documented to improve symptoms
and/or prognosis. Overall, currently available therapies
have resulted in a reduction of hospitalization events of
30–50% in comparison to the era before the introduc-
tion of ACE-inhibitors and beta-blockers [1], the current
cornerstones of heart failure therapy.
Still, the outcome of patients with advanced heart fail-
ure in New York Heart Association Class III-IV remains
poor. The 5-year mortality of patients hospitalized for
heart failure is still approximately 50%, worse than many
cancers [2]. For these patients with advanced stages of
the disease and persistent symptoms under optimal ther-
apy, orthotopic heart transplantation serves as an im-
portant treatment option to improve quality of life and
prognosis. However, this treatment is limited by the
availability of donor organs. In Germany, the mismatch
between patients on the waiting list and available donor
organs is growing and following the public discussion of
recent physician misconduct in organ allocation for liver
transplantation, donor numbers have come to a historic
low (http://www.dso.de/dso-pressemitteilungen/einze-
lansicht/article/zahl-der-organspender-in-2013-weiter-
stark-gesunken.html). Therefore, the allocation of the
few available organs to the large number of patients in
demand is a growing medical and ethical dilemma.
In the Eurotransplant region, organ allocation is prior-
itized by waiting time and medical urgency, where pa-
tients can be assigned a high-urgency (HU) status if they
fulfill specific criteria of disease severity. While initially
introduced as a rare exception to bypass the regular
waiting list to allow transplantation within a period of
days to a few weeks, it has now become the rule. Due to
the growing number of patients on HU-status and the
decline in organ donation, currently more than 80% of
cardiac transplantation are performed on HU-status [3],
resulting in a predominant organ allocation to the very
sick patients, which intrinsically have a worse outcome
also after transplantation.
Several approaches have been proposed to account for
this ethical dilemma, including the prioritization of reg-
istered donors as potential recipients [4] or a change in
the rules for consent to organ donation [5]. Recently, a
novel scoring system for prioritization was proposed by
a consortium of large European transplant centers and
Eurotransplant that takes into account both waiting list
mortality as well as expected post-transplant prognosis.
In analogy to the established scheme for lung transplant-
ation (the Lung Allocation Score), this novel (and so far
theoretic) system was termed “Cardiac Allocation Score”
(CAS) and tested on a Eurotransplant cohort of 448
patients for whom high urgency status had been applied
for [6]. However, baseline characteristics of listed pa-
tients and outcome differs to a certain degree between
centers and so far no published data exists on how such
novel scoring system would relate to a single center
transplant population. In addition, currently no pub-
lished data exist on CAS-values outside the high-
urgency population. Here, we therefore performed a
retrospective calculation of the CAS for a cohort of 73
patients transplanted in our medium-volume transplant
center in Southern Germany, including patient on all
Eurotransplant urgency levels, to assess the distribution




From the 300 patients that underwent cardiac trans-
plantation at the University Heart Center Freiburg-Bad
Krozingen between 1994 and 2013, we selected a cohort
that included all patients that were recruited for heart-
only transplantation and that underwent transplantation
and long-term follow up in Freiburg. For this analysis,
we excluded pediatric patients aged <18 years as well as
patients that were recruited and followed up outside of
our department or in associated hospitals. These selec-
tions yield a study population of 92 patients, with a
complete dataset enabling CAS-calculation for 73
patients. We included patients on all urgency levels. We
did not analyze patients that were listed for heart trans-
plantation but died on the waiting list.
Pre transplant mortality model
We used the Seattle Heart Failure Model (SHFM) to
retrospectively calculate the theoretical waiting list
mortality for our patients, as this prediction model was
recently shown to have superior predictive value in com-
parison to other prediction models [6]. This mortality
model includes hemodynamic parameters as well as
functional status and data on medication and devices
[7]. As our analysis was limited to patients that survived
to transplantation, our retrospective calculation cannot
be regarded as a validation of the score for our cohort,
but was performed to allow the calculation of the CAS
as described below.
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Prediction of post-transplant mortality
We retrospectively validated two previously published
mortality prediction models on our patient cohort: The
Index for Mortality Prediction After Cardiac Transplant-
ation (IMPACT) includes 12 recipient specific variables
(age greater than 60, bilirubin, creatinine clearance, dia-
lysis between listing and transplant, female sex, heart
failure aetiology, infection, IABP, mechanical ventilation
prior to transplant, race, temporary circulatory support,
ventricular assist device) that are weighted and eventu-
ally yield a theoretical score range between 0 and 50
points. The original study design of the Impact-score ex-
cluded patients with a total artificial heart. Each value
stands for a defined risk of one year mortality [8]. For
our data set we separated our patient cohort in a low
(0–8 points) and a high risk (>8 pts.) group.
As a second mortality model, the CARRS score was
calculated for all patients. The name of this score is an
acronym of the five included variables (cerebral vascular
accident, albumin, re-HTx, renal dysfunction and prior ster-
notomies). Patients can be stratified in a high and a low risk
group (0–2 pts. and >3 pts.) with a maximum of 9 points
[9]. For the IMPACT-score, we chose a value of 8 points as
a cut-off, as this value identifies a population with a high 1-
year mortality of >15%, which we defined as high risk.
Cardiac allocation score
The hypothetical Cardiac Allocation Score (CAS) was
calculated based on the combination of the SHFM for
theoretical mortality on the waiting list and the IMPACT
score for post-transplant mortality prediction as recently
described by Smits and coworkers [6]. Eventually, the
CAS is a combination of these two scores that is ad-
justed to yield a maximum value of 100. Higher values
identify patients with a high predicted mortality on the
waiting list, but only if their predicted survival probabil-
ity after cardiac transplantation is also high. Thus, the
score prioritizes patients with the most benefit with
regards to life time gained by cardiac transplantation.
Results
Demographics of the study cohort
We analysed a data set of 92 patients. Seventy-three
(79.3%) patients were male with a mean age of 50.7 years.
Nineteen (20.7%) were female (52.5 years). For CAS-
calculation 19 patients were excluded because they were
supported by a total artificial heart (which prohibits cal-
culation of the IMPACT-score) or because data of essen-
tial variables could not be retrieved. Thirty-eight (41.3%)
were supported by a VAD at time of transplantation, 8
were on extracorporal mechanical circulatory support.
Thirty-nine (42.4%) were transplanted from T status, 53
(57.6%) from U or HU status. Patient characteristics are
shown in Table 1.
Post-transplant survival
In our patient cohort, only the IMPACT score significantly
predicted survival (Fig. 1). Patients in the higher risk
stratum of the CARRS score showed a trend towards lower
survival, but this did not reach statistical significance
(p = 0.411, Fig. 2). Patients transplanted on HU-status had
a higher IMPACT score than patients on T status at time
of transplant (7.17 vs 4.11 see Table 2). The IMPACT score
was predictive for survival both in the total patient cohort
as well as in the VAD-supported patients. Interestingly,
patients with a low waiting list mortality before transplant
predicted by the SHFM also showed a trend for better
survival after transplantation in our cohort (Fig. 3).
Cardiac allocation score
The SHFM and the impact score were used to calculate a
hypothetical retrospective cardiac allocation score for each
patient. The distribution of the resulting values with mean
of 32 (30–34; 95% confidence interval) is shown in Fig. 4.
Patients transplanted from a VAD had on average a lower
CAS than patients transplanted without a VAD (mean
26.26 vs 35.29, p < 0.001, Fig. 5). There was a large overlap
in CAS values between patients transplanted from HU/U
Table 1 Baseline Characteristics
Variables
Age, years 54 (18–72; 16)
Weight, kg 78 (44–123; 20)
Body mass index, kg/m2 25.5 (17.2–38.8; 5)






High urgency, % 56.5
Ventricular assist devicea, % 43.2
IABP, % 12
Mechanical support (ECMO, ECLS), % 8.7
Sodium, mmol/L 138 (129–143; 4)
Creatinine, mg/dl 1.08 (0.46–3.38; 0.5)
Creatinine Clearance, ml/min 87 (31–218; 45.5)
Bilirubin, mg/dl 0.8 (0.2–5.2; 0.9)
Total Cholesterol, mg/dl 181 (95–304; 77)
Uric acid, mg/dl 6.3 (1.5–14.4; 2.6)
Hemoglobin, g/dl 11.8 (7.8–17.7; 4.1)
LVEF, % 17.3 (5–82; 5)
Data are presented as median (minimum-maximum; interquartile range)
IABP intra-aortic balloon pump, ECMO extracorporeal membrane oxygenation,
ECLS extracorporeal life support
aFour Patients with Total Artificial Heart were not included
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vs T status, with a median of 29 (27–34; 95% CI) for the
HU/U cohort vs 35 (31–37; 95% CI) for the Tcohort (Fig. 6).
Discussion
The contemporary confrontation with the dilemma of a
growing waiting list and a sicker patient population
demands a fair allocation system for cardiac transplantation
with clearly defined criteria. While medical urgency and
waiting time currently determine the priority for organ
allocation, the current system in Germany already demands
that the treating physicians take into account the expected
outcome after transplantation when listing patients for
Fig. 1 Kaplan-Meier survival curves after heart transplantation (Impact-Score)
Fig. 2 Kaplan-Meier survival curves after heart transplantation (CARRS-Score)
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transplant [10]. Yet, how precisely such a prognostic predic-
tion should be made remains undefined and currently leaves
ample room for interpretation. In Germany, an increasing
public and political interest and involvement in the issue of
organ allocation could be observed in the past year, e.g.
when the suitability of a pediatric patient with congenital
heart disease and cerebral deficits after survived cardiac ar-
rest was controversially discussed. The definition of clear
medical and ethical standards is therefore essential to en-
sure a fair and transparent allocation process and to protect
patients and physicians from external influence and judicial
compromise.
For patients awaiting lung transplantation, a lung alloca-
tion score (LAS) was recently introduced in Germany. In
contrast to the current practice in heart transplantation,
this score prioritizes patients with a high expected mortal-
ity on the waiting list, but only if a high benefit from
transplantation is also expected and post post-transplant
prognosis is favorable. The recently proposed Cardiac Al-
location Score largely follows this reasoning, to maximize
the effect of each cardiac transplantation and to gain the
most benefit per organ.
Essentially, the proposed CAS is a combination of two
scores: one to calculate the expected mortality on the






> 60 27 14 (35.9%) 13 (24.5%)
≤ 60 65 25 (64.1%) 40 (75.5%)
Bilirubin, mg/dl 0.050
0-0.99 53 28 (77.8%) 25 (49.0%)
1-1.99 27 6 (16.7%) 21 (41.2%)
2-3.99 6 2 (5.6%) 4 (7.8%)
≥ 4 1 0 1 (2.0%)
Creatinine Clearance, ml/min 0.752
≥ 50 75 30 (85.7%) 45 (88.2%)
30-49 11 5 (14.3%) 6 (11.8%)
< 30 0 0 0
Dialysis between listing and transplant 5 1 (2.7%) 4 (7.5%) 0.645
Female sex 19 12 (30.8%) 7 (13.2%) 0.040
Diagnosis 0.036
Ischemic 46 16 (41.0%) 30 (56.6%)
Idiopathic 34 20 (51.3%) 14 (26.4%)
Congenital 5 0 5 (9.4%)
Other 7 3 (7.7%) 4 (7.5%)
Infection 13 1 (2.7%) 12 (22.6%) 0.026
IABP 11 1 (2.7%) 10 (18.9%) 0.024
Mechanical ventilation prior to Tx 2 0 2 (3.8%) 0.510
Circulatory support 8 0 8 (15.1%) 0.019
Ventricular assist deviced <0.001
No VAD 50 34 (87.2%) 16 (32.7%)
Early Generation PFb 23 3 (7.7%) 20 (40.8%)
New Generation CFc 3 0 3 (6.1%)
Heartmate II 12 2 (5.1%) 10 (20.4%)
Race is not listed because all patients were Caucasian
IABP Intraaortic balloon pump, Tx Transplantation
ap value based on X2 test or Fisher’s exact test
bEarly Generation pulsatile flow includes Heartmate I, Thoratec (LVAD,RVAD,BVAD)), Novacor
cNew Generation continuous flow includes Jarvik, Incor, Ventracor
d4 Patients with total artificial heart were not included
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waiting list while the patient is waiting for an organ and
a second score to calculate the expected prognosis of the
individual patient after transplantation. The detailed
methodology is described in the original publication by
Smits and coworkers [6]. Briefly, after calculating ex-
pected mortality before and after transplantation, these
risks are weight against a baseline population risk. The
CAS is then derived by subtracting these two values and
by performing a statistical adjustment to yield values
between 1 and 100.
After evaluation of several prediction models, Smits et al.
eventually chose the Seattle Heart Failure Model (SHFM)
for prediction of waiting list mortality and the Index for
Mortality Prediction After Cardiac Transplantation (IM-
PACT) score for prediction of prognosis after transplant-
ation. In our current report, we now retrospectively tested
Fig. 3 Kaplan-Meier survival curves after heart transplantation (SHFM-Score)
Fig. 4 Distribution of the CAS-values across the whole cohort
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the predictive value of two models for estimation of post-
transplant survival: The IMPACT and the CARRS-score.
We found the IMPACT-score superior in its ability to pre-
dict prognosis in our patient population, also because of
the small number of patients in our cohort in the high risk
stratum of the CARRS-score.
While Smits et al. tested their model in a larger Euro-
transplant cohort from whom high urgency or urgency
status was requested in an 8 months period, our study
describes a mixed population of patients transplanted on
all levels of urgency including a large number of patients
on T-status. Interestingly, there is a significant overlap
in CAS-values between the different levels of urgency,
indicating that the inclusion of post-transplant benefit in
the allocation algorithm will result in a significant alter-
ation of organ distribution between the current urgency
groups. This is a more than marginal affect, as in our pa-
tient population the average CAS score of the patients
Fig. 6 CAS-values of patients transplanted on T status and on HU-status
Fig. 5 Distribution of CAS values in patients on VAD-support and without VAD
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on T-status was even higher than of the patients on HU-
status that survived to transplant.
One still open question is how to best include the
patients on mechanical support into the distribution
algorithm. As these patients usually do not die directly
from heart failure, their mortality risk is not adequately
reflected by the SHFM-value, which would result in an
unwanted disadvantage in the CAS allocation algorithm.
The currently proposed solution to this dilemma would
be an adjustment of the CAS by 2–3 points, to account
for increased non-heart failure related mortality risk, e.g.
by infection and stroke. However, in our patient popula-
tion, the average CAS-value of VAD-supported patients
remained on average lower than of non-VAD-supported
patients. Interestingly, this was primarily not due to the
SHFM-component of the CAS, as one could expect, but
due to a higher IMPACT-score. Looking at the individ-
ual parameters of this prediction model, infection was
significantly more common in VAD-supported pa-
tients, which resulted in a higher IMPACT and lower
CAS-value. As VAD-related infections can result in
an upgrade to high-urgency status (and therefore a
higher likelihood of transplantation in the past), one
can only speculate on the potential implications of
this factor upon introduction of the CAS, when the
current high-urgency system will be abandoned. In
how far the Cardiac Allocation Score has to be fur-
ther adjusted for patients with VAD-complications
remains to be determined on the solid statistical basis
of a larger cohort.
Our study has several limitations. Obviously, this is a
retrospective single center study on patients recruited and
followed up in our center, therefore all statistical analyses
are limited by the sample size. In addition, several of our
patients had to be excluded, e.g. because of support by a
total artificial heart which does not allow CAS-calculation.
Our comparison of CAS-values in patients transplanted
on T or HU-status is intrinsically also a comparison of dif-
ferent decades, as in the recent past, transplantation from
T-status was a rare exception in our center as well as
Germany as a whole. Furthermore, our studies focused ex-
clusively on patients that survived to transplantation and
therefore allows no conclusion about the urgency-
component of the CAS, as patients that died on the wait-
ing list were not included in the analysis.
Conclusion
Currenty, the CAS is not used for organ allocation in our
institution, but remains one of the possible options for the
currently ongoing revision process of organ allocation
practice in the Eurotransplant region. Our analysis com-
prises the first published overview of the distribution of
CAS-values in an individual transplant center and gives a
first expression how the introduction of the CAS could
affect organ allocation in the real world.
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